Erysipelas and Cellulitis
Authors:
J. Nováková 1,2
Authors‘ workplace:
Kožní oddělení Fakultní nemocnice Ostrava přednosta prim. MUDr. Yvetta Vantuchová, Ph. D.
1; Lékařská fakulta Ostravské univerzity, katedra interních oborů
2
Published in:
Čes-slov Derm, 93, 2018, No. 2, p. 51-66
Category:
Reviews (Continuing Medical Education)
Overview
In the Anglo-Saxon literature, erysipelas is defined as an acute infectious disease affecting the superficial dermis as well as the lymphatics. The term “cellulitis” then refers to a deeper process involving the reticular dermis and subcutaneous fat tissue, which clinically, unlike erysipelas, exhibits less sharp borders of erythema. In clinical practice, as well as in this article, the term erysipelas is usually used for both of these conditions. The most common etiologic agents are the beta-hemolytic group A streptococci. Typically, erysipelas and cellulitis present as acute diseases with characteristic local and general symptoms, the treatment of choice are antibiotics. It is a disease with predisposing factors, a disease with a tendency to recurrence, and lasting consequences. From the epidemiological point of view, it is an infectious disease with possible transmission to other persons. The article provides an overview of current knowledge about clinical picture and treatment of this disease.
This article provides a review of current knowledge about clinical picture and treatment of these diseases.
Key words:
erysipelas – cellulitis – Streptococcus pyogenes – antibiotic treatment – prophylactic treatment
Sources
1. ADÁMKOVÁ, V. Antibiotická léčba infekcí kůže a měkkých tkání – současné možnosti a limity. REMEDIA, 2015, 25, p. 150–153.
2. Česká lékařská společnost Jana Evangelisty Purkyně. Subkomise pro antibiotickou politiku. Konsenzus používání antibiotik I. Penicilinová antibiotika. Dostupné na www: www.infekce.cz/standardy (Společnost infekčního lékařství ČLS JEP).
3. Česká lékařská společnost Jana Evangelisty Purkyně. Subkomise pro antibiotickou politiku. Konsenzus používání antibiotik II. Makrolidová antibiotika. Praktický lékař, 2016, 96, 4, p. 166–178.
4. Česká lékařská společnost Jana Evangelisty Purkyně. Subkomise pro antibiotickou politiku. Konsenzus-cefalosporiny. Praktický lékař, 2016, 96, 1, p. 32–50.
5. BAUER, S., AUBERT C. E., RICHLI, M. et al. Blood cultures in evaluation of uncomplicated cellulitis. European Journal of Internal Medicine, 2016, 36, p. 50–56.
6. BENEŠ, J. Infekční lékařství. První vydání. Galén, 2009, p. 203–205.
7. BOLOGNIA, J. L., JORIZZO, J. L., SHAFFER et al. Dermatology. Third edition, Elsevier, 2012, II, p. 1196–1198.
8. BRAUN-FALCO, O., PLEWIG, G., WOLFF, H. H., BURGDORF, W. H. C. Dermatology. Second, Completly Revised Edition, Springer-Verlag Berlin Heidelberg New York, 2000, p. 157–159.
9. BREIMAN, R. F., DAVIS, J. P., FACKLAM, R. R. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA, 1993, Jan 20. 269, 3, p. 390–391.
10. BRODELL, L. A., BRODELL, J. D., BRODELL, B. T. Recurrrent lymphangitic cellulitis syndrome: A quintessential example of an immunocompromised district, Clinics in Dermatology, 2014, 32, p. 621–627.
11. COX, H. N. Management of lower leg cellulitis. Clinical Medicine, 2002, 2, p. 23–27.
12. ČEŠKA, R. Interna, 2. vydání, Triton 2015, p. 670–671.
13. DALAL, A., ESKIN-SCHWARTZ, M., MIMOUNI, D. et al. Interventions for the prevention of recurrent erysipelas and cellulitis. Cochrane Database of Systematic Rewiews, 2017, Art. Nu CD009758.
14. DAMSTRA, R. J., VAN STEENSEL, M. A. M., BOOMSMA, J. H. B. et al. Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patietns with unilateral erysipelas of the leg. British Journal of Dermatology, 2008, 158, 6, p. 1210–1215.
15. DAVIS, L. Erysipelas. Medscape, Updated Sep. 12, 2017.
16. DE GODOY, J. M., MASSARI, P. G., ROSINHA, M. Y. et al. Epidemiological Data and Comorbidities of 428 Patients Hospitalized With Erysipelas. Angiology, 2010, 61, 5, p. 492–494.
17. DE GODOY, J. M., DE GODOY, M. F., VALENTE, A. Lymphoscintigraphic evaluation in patients after erysipelas. Lymphology, 2000, 33, 4, p. 177–180.
18. GROSSHANS, E. M. The Red Face: Erysipelas. Clinics in Dermatology, 1993, 11, p. 307–313.
19. GUNDERSON, C. G., CHANG, J. J. Risk of deep vein trombosis in patients with cellulitis and erysipelas. A systematic review and meta-analysis. Trombosis Research, 2013, 132, p. 336–340.
20. HERCHLINE, T. E. Cellulitis, Medscape, Updated Jul 05, 2017.
21. HERLE, P., APPELT, J. Erysipel. Doporučené postupy pro praktické lékaře, 2002.
22. HIRMEROVÁ, J., KARETOVÁ, D., MALÝ, R. et al. Akutní žilní trombóza 2014: současný stav prevence, diagnostiky a léčby. Doporučený postup České angiologické společnosti ČLS JEP.
23. HIRSCHMANN, J. V., RAUGI, G. J. Lower limb cellulitis and its mimics. Part I. J. Am. Acad. Dermatol., 2012, 67, p. 163.e1–163.e8.
24. HIRSCHMANN, J. V., RAUGI, G. J. Lower limb cellulitis and its mimics. Part II. Conditions that simulate lower limb cellulitis. J. Am. Acad. Dermatol., 2012, 67, p. 177.e1– 177.e9.
25. CHLEBICKI, M. P., OH, CH. CH. Reccurent Cellulitis: Risk factors, etiology, pathogenesis and treatment. Curr. Infect. Dis. Rep., 2014, p. 16:422.
26. INGHAMMAR, M., RASMUSSE, M., LINDER, A. Reccurent erysipelas – risk factors and clinical presentation. Infectious Diseases, 2014, p. 14:270.
27. KAREN, I., KOLEK, V., MATOUŠKOVÁ, M. et al. Antibiotická terapie respiračních, močových a kožních infekcí v ambulanci všeobecného praktického lékaře. Aktualizace 2014.
28. KARPPELIN, M., SILJANDER, T., HAAPALA, A. M. et al. Evidence of streptococcal origin of acute non-necrotising cellulitis: a serogical study. Eur J Clin. Microbiol. Infect. Dis., 2015, 34, p. 669–672.
29. KILBURN, S. A., FEATHERSTONE, P., HIGGINS, B. et al. Interventions for cellulitis and erysipelas. Cochrane database of systematic reviews, 2010, Iss6.
30. KO, C. C., LEE, H. C. H., SAFDAR, H. Y. et al. Antibiotic prophylaxis for preventing reccurent cellulitis: A systemic review and metaanalysis. Journal of Infection, 2014, 69, p. 26–34.
31. KOSTER, J. B., KULLBERG, B. J., VAN DER MEER J. W. M. Reccurent erysipelas despite antibiotic prophylaxis: an analysis from case studies. The Netherlands Journal of Medicine, 2007, 65, p. 89–94.
32. KRASAGAKIS, K., VALACHIS, A., MANIATAKIS, P. et al. Analysis of epidemiology, clinical features and managenemt of erysipelas. International Journal of Dermatology, 2010, 49, p. 1012–1017.
33. LEPPARD, B. J., SEAL, D. V., COLMAN, G. et al. The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas. British Journal of Dermatology, 1985, 112, p. 559–567.
34. LOVEČKOVÁ, Y. Antibiotika v dermatologii z pohledu mikrobiologa. Dermatologie pro praxi, 2012, 6, 2, p. 74–76.
35. PICARD, D., KLEIN, A., GRIGIONI, S. et al. Risk factors for abscess formation in patients with superficial cellulitis (erysipelas) of the leg. Brit. Jour. of Der., 2013, 168, p. 859–863.
36. PISO, R. J., POP, R., WIELAND, M. et al. Low sensitivity of needle aspiration cultures in patients with cellulitis/erysipelas. Springer plus, 2016, 5, p. 1578.
37. POLANECKÝ, V., GOPFERTOVÁ, D. Manuál praktické epidemiologie. Díl 1. IPVZ, 2015.
38. RAFF, B. A., KROSHINSKY, D. Cellulitis. A Review. JAMA, 2016, p. 325–332.
39. STEVENS, D. L., BISNO, A. L., CHAMBERS, H. F. et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America Clinical Infectious Diseases. 2014, 59, 2, p. pe10-e.
40. ŠTORK, J. et al. Dermatovenerologie. 2008, Galén, p. 90–91.
41. THOMAS, K. S., CROOK, A. M., NUNN, A. J. et al. For the UK Dermatology Networks PATCH I Trial Team, Penicillin to Prevent Recurrent Leg Cellulitis. N. Engl. J. Med., 2013, 368, p. 1695–1703.
42. THOMAS, K., CROOK, K., FOSTER, K. et al. Clinical Trial Networks PATCH Trial Team. Prophylactic antibiotics for prevention of cellulits (erysipelas) of the leg: results of the U.K. Dermatology Clinical Trials Networks PATCH II Trial. Br. J. Dermatol., 2012,166, 1, p. 169–178.
43. VIGNES, S., DUPY, A. Reccurence of lymphoedema-associated cellulitis (erysipelas) under prophylactic antibiotherapy: a retrospective cohort study. JEADV, 2006, 20, p. 818–822.
44. VIKTORINOVÁ, M., KARLOVÁ, I., KOUKALOVÁ, D. et al. Erysipel – retrospektivní studie za období 1996–2000. Česko-slovenská dermatologie, 2002, 5, p.195–202.
45. VÍTOVÁ, V., VÍTOVÁ, H., HRUBÁ, D. Péče o komplikovaný lymfedém provázející specifické malignity u žen- vybrané kazuistiky. Interní medicína praxi, 2011, 13, p. 214–218.
46. WENG, Q. Y., RAFF, A. B., COHEN, J. M. Costs and Consequences Associated With Misdiagnosed Lower Extremity Cellulitis. JAMA Dermatol., 2017, 153, p. 141–146.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2018 Issue 2
Most read in this issue
- Erysipelas and Cellulitis
- Mycotic Skin Infection Caused by Arthroderma benhamiae (Trichophyton sp.)
- Tubera Mulgentium – Case Description